Companies: 10,795·Total market cap: $144.5T
DICE Therapeutics, Inc.

DICE Therapeutics, Inc.

DICENASDAQHealthcare
$47.55
+$0.03(+0.06%)
Market Cap$2.3B
P/E Ratio
52W High$47.9
52W Low$15.08

DICE Therapeutics, Inc. (DICE) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

dice · pe ratio · data through Dec 31, 2022

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for DICE Therapeutics, Inc. (DICE) measures how much investors pay for each dollar of the company's trailing earnings. DICE's current PE ratio of N/A is calculated by dividing its stock price of $47.55 by its TTM earnings per share of -$2.07.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31

Forward P/E
N/A
EPS (TTM)
-$2.07
TTM · diluted EPS
PEG Ratio
-0.64
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · DICE Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2022 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
DICE Therapeutics, Inc.
DICE Therapeutics, Inc.You
DICE
$2.3BN/A-$2.07
BELLUS Health Inc.
BELLUS Health Inc.
BLU
$1.9BN/A-$0.66
Calliditas Therapeutics AB (publ)
Calliditas Therapeutics AB (publ)
CALT
$2.1BN/A-$17.37
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc.
DCPH
$2.2BN/A-$2.29
Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc.
FUSN
$1.8BN/A-$1.45
Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc.
KDNY
$2.7BN/A-$2.87
Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc.
LBPH
$2.3BN/A-$2.39

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 4 of 4 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2022-12-31Latest
FY2022
$-2.07
2021-12-31
FY2021
$-3.91
2020-12-31
FY2020
$-1.02
2019-12-31
FY2019
$-0.56

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for DICE Therapeutics, Inc. (DICE) measures how much investors pay for each dollar of the company's trailing earnings. DICE's current PE ratio of N/A is calculated by dividing its stock price of $47.55 by its TTM earnings per share of -$2.07.

PE Ratio = Stock Price ÷ EPS (TTM)
= $47.55 ÷ -$2.07 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

DICE pe ratio · 6 questions

DICE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $47.55 and TTM EPS of -$2.07. Data sourced from Financial Modeling Prep via DICE's SEC 10-K and 10-Q filings.

DICE PE ratioWhat is DICE PE ratioCurrent PE ratio of DICEDICE PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · DICE Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09